NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $42.00
  • Forecasted Upside: 287.45 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$10.84
▲ +0.04 (0.37%)
1 month | 3 months | 12 months
Get New Opiant Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OPNT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OPNT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$42.00
▲ +287.45% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Opiant Pharmaceuticals in the last 3 months. The average price target is $42.00, with a high forecast of $42.00 and a low forecast of $42.00. The average price target represents a 287.45% upside from the last price of $10.84.
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Opiant Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/26/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/1/2020Northland SecuritiesReiterated RatingBuy$42.00High
i
11/7/2019Northland SecuritiesReiterated RatingBuy$42.00Medium
i
Rating by Carl Byrnes at Northland Securities
10/18/2019Northland SecuritiesReiterated RatingBuy$42.00Medium
i
8/2/2019Northland SecuritiesReiterated RatingBuyHigh
i
5/29/2019Northland SecuritiesInitiated CoverageOutperform ➝ Outperform$42.00High
i
10/4/2018Cantor FitzgeraldSet Price TargetBuy$42.00Low
i
Rating by Brandon Folkes at Cantor Fitzgerald
9/28/2018Cantor FitzgeraldSet Price TargetOverweight ➝ Buy$32.00 ➝ $42.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
8/28/2018Cantor FitzgeraldSet Price TargetBuy$32.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
8/9/2018Cantor FitzgeraldSet Price TargetBuy$32.00High
i
Rating by Brandon Folkes at Cantor Fitzgerald
7/30/2018Cantor FitzgeraldSet Price TargetBuy$32.00Medium
i
Rating by Brandon Folkes at Cantor Fitzgerald
6/14/2018Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by B. Folkes at Cantor Fitzgerald
6/11/2018Cantor FitzgeraldInitiated CoverageBuy$32.00High
i
(Data available from 4/18/2016 forward)
Opiant Pharmaceuticals logo
Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.
Read More

Today's Range

Now: $10.84
$10.70
$10.92

50 Day Range

MA: $11.51
$10.36
$13.73

52 Week Range

Now: $10.84
$6.79
$14.98

Volume

7,218 shs

Average Volume

41,135 shs

Market Capitalization

$46.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Opiant Pharmaceuticals?

The following equities research analysts have issued reports on Opiant Pharmaceuticals in the last twelve months: Northland Securities, and TheStreet.
View the latest analyst ratings for OPNT.

What is the current price target for Opiant Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Opiant Pharmaceuticals in the last year. Their average twelve-month price target is $42.00, suggesting a possible upside of 287.5%. Northland Securities has the highest price target set, predicting OPNT will reach $42.00 in the next twelve months. Northland Securities has the lowest price target set, forecasting a price of $42.00 for Opiant Pharmaceuticals in the next year.
View the latest price targets for OPNT.

What is the current consensus analyst rating for Opiant Pharmaceuticals?

Opiant Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe OPNT will outperform the market and that investors should add to their positions of Opiant Pharmaceuticals.
View the latest ratings for OPNT.

What other companies compete with Opiant Pharmaceuticals?

How do I contact Opiant Pharmaceuticals' investor relations team?

Opiant Pharmaceuticals' physical mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company's listed phone number is 310-598-5410 and its investor relations email address is [email protected] The official website for Opiant Pharmaceuticals is www.opiant.com.